PE20201171A1 - Anticuerpos de cadena pesada que se unen a cd22 - Google Patents
Anticuerpos de cadena pesada que se unen a cd22Info
- Publication number
- PE20201171A1 PE20201171A1 PE2020000809A PE2020000809A PE20201171A1 PE 20201171 A1 PE20201171 A1 PE 20201171A1 PE 2020000809 A PE2020000809 A PE 2020000809A PE 2020000809 A PE2020000809 A PE 2020000809A PE 20201171 A1 PE20201171 A1 PE 20201171A1
- Authority
- PE
- Peru
- Prior art keywords
- heavy chain
- seq
- nos
- joining
- chain antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Abstract
Se refiere a un anticuerpo de cadena pesada sola que se une a CD22, que comprende una region variable de cadena pesada que comprende: (a) una CDR1 que tiene dos o menos sustituciones en cualquiera de las secuencias de aminoacidos de las SEQ ID NOs: 1 a 10; y/o (b) una CDR2 que tiene dos o menos sustituciones en cualquiera de las secuencias de aminoacidos de las SEQ ID NOs: 11 a 17; y/o (c) una CDR3 que tiene dos o menos sustituciones en cualquiera de las secuencias de aminoacidos de las SEQ ID NOs: 18 a 23; asi como una region variable de cadena pesada que tiene al menos un 95% de identidad de las SEQ ID NOs: 24 a 84. Tambien se refiere a metodos para elaborar dicho anticuerpo, composiciones y su uso para tratar trastornos de linfocitos B que se caracterizan por la expresion de CD22
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762609759P | 2017-12-22 | 2017-12-22 | |
PCT/US2018/067299 WO2019126756A1 (en) | 2017-12-22 | 2018-12-21 | Heavy chain antibodies binding to cd22 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20201171A1 true PE20201171A1 (es) | 2020-10-28 |
Family
ID=65041936
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2020000809A PE20201171A1 (es) | 2017-12-22 | 2018-12-21 | Anticuerpos de cadena pesada que se unen a cd22 |
Country Status (21)
Country | Link |
---|---|
US (2) | US11873336B2 (es) |
EP (1) | EP3728319A1 (es) |
JP (1) | JP2021506325A (es) |
KR (1) | KR20200104342A (es) |
CN (1) | CN111683966B (es) |
AU (1) | AU2018392088A1 (es) |
BR (1) | BR112020012554A2 (es) |
CA (1) | CA3086665A1 (es) |
CL (2) | CL2020001703A1 (es) |
CO (1) | CO2020008925A2 (es) |
CR (1) | CR20200322A (es) |
EA (1) | EA202091557A1 (es) |
EC (1) | ECSP20042489A (es) |
IL (1) | IL275498A (es) |
JO (1) | JOP20200157A1 (es) |
MX (1) | MX2020006494A (es) |
NI (1) | NI202000050A (es) |
PE (1) | PE20201171A1 (es) |
PH (1) | PH12020550964A1 (es) |
SG (1) | SG11202005880XA (es) |
WO (1) | WO2019126756A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112018076767A2 (pt) | 2016-06-21 | 2019-04-02 | Teneobio, Inc. | anticorpos de ligação a cd3 |
WO2018052503A1 (en) | 2016-09-14 | 2018-03-22 | Teneobio, Inc. | Cd3 binding antibodies |
CN117567624A (zh) | 2017-06-20 | 2024-02-20 | 特纳奥尼股份有限公司 | 仅有重链的抗bcma抗体 |
KR20200104342A (ko) | 2017-12-22 | 2020-09-03 | 테네오바이오, 인코포레이티드 | Cd22에 결합하는 중쇄 항체 |
AU2020291938A1 (en) * | 2019-06-14 | 2022-01-20 | Teneobio, Inc. | Multispecific heavy chain antibodies binding to CD22 and CD3 |
KR20210143097A (ko) * | 2020-05-19 | 2021-11-26 | (주)이노베이션바이오 | Cd22에 특이적인 항체 및 이의 용도 |
AU2021307644A1 (en) * | 2020-07-16 | 2023-02-16 | Legend Biotech Ireland Limited | CD22 binding molecules and uses thereof |
Family Cites Families (70)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
AU728657B2 (en) | 1996-03-18 | 2001-01-18 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
JP2003531588A (ja) | 2000-04-11 | 2003-10-28 | ジェネンテック・インコーポレーテッド | 多価抗体とその用途 |
GB0115256D0 (en) | 2001-06-21 | 2001-08-15 | Babraham Inst | Mouse light chain locus |
CA2499300A1 (en) | 2002-10-31 | 2004-05-21 | Genentech, Inc. | Methods and compositions for increasing antibody production |
US7575893B2 (en) | 2003-01-23 | 2009-08-18 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
EP3272770B1 (en) | 2004-07-22 | 2023-12-20 | Erasmus University Medical Center Rotterdam | Method for the production of a vh heavy chain-only antibody in a transgenic mammal and binding polypeptide complex consisting of a dimer of a first chain and a second chain wherein each chain consists of two antigen-specific vh binding domains linked by a dimerisation domain |
US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
WO2008119567A2 (en) | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific cd3-epsilon binding domain |
EP2602323B1 (en) | 2007-06-01 | 2018-02-28 | Open Monoclonal Technology, Inc. | Compositions and methods for inhibiting endogenous immunoglobin genes and producing transgenic human idiotype antibodies |
US20100122358A1 (en) | 2008-06-06 | 2010-05-13 | Crescendo Biologics Limited | H-Chain-only antibodies |
CN102203135A (zh) | 2008-09-19 | 2011-09-28 | 米迪缪尼有限公司 | 对抗sonic hedgehog同系物的抗体及其用途 |
ES2588155T3 (es) | 2008-10-01 | 2016-10-31 | Amgen Research (Munich) Gmbh | Anticuerpo biespecífico de cadena sencilla PSMAxCD3 específico entre especies |
PT2406284T (pt) | 2009-03-10 | 2016-09-29 | Biogen Ma Inc | Anticorpos anti-bcma |
GB0905023D0 (en) | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
ME02646B (me) | 2010-02-08 | 2017-06-20 | Regeneron Pharma | Miš sa zajedničkim lakim lancem |
TWI653333B (zh) | 2010-04-01 | 2019-03-11 | 安進研究(慕尼黑)有限責任公司 | 跨物種專一性之PSMAxCD3雙專一性單鏈抗體 |
EP2640750A1 (en) | 2010-11-16 | 2013-09-25 | Boehringer Ingelheim International GmbH | Agents and methods for treating diseases that correlate with bcma expression |
WO2012122528A1 (en) | 2011-03-10 | 2012-09-13 | Hco Antibody, Inc. | Bispecific three-chain antibody-like molecules |
WO2012122512A1 (en) | 2011-03-10 | 2012-09-13 | Hco Antibody, Inc. | Recombinant production of mixtures of single chain antibodies |
TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對bcma之e3以及cd3的結合分子 |
UA119227C2 (uk) | 2012-04-20 | 2019-05-27 | Аптево Рісьорч Енд Девелопмент Ллс | Поліпептид, що зв'язується з cd3 |
AU2013251482B2 (en) | 2012-04-26 | 2018-01-04 | Bioatla Llc | Anti-CD22 antibodies |
US20150203591A1 (en) | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
CN104994729B (zh) | 2012-12-14 | 2019-01-11 | Omt公司 | 编码具有人独特型的啮齿动物抗体的多核苷酸以及包含所述多核苷酸的动物 |
US10077315B2 (en) | 2013-02-05 | 2018-09-18 | Engmab Sàrl | Bispecific antibodies against CD3 and BCMA |
AR095374A1 (es) | 2013-03-15 | 2015-10-14 | Amgen Res (Munich) Gmbh | Moléculas de unión para bcma y cd3 |
WO2015095412A1 (en) | 2013-12-19 | 2015-06-25 | Zhong Wang | Bispecific antibody with two single-domain antigen-binding fragments |
DK3105252T3 (da) | 2014-02-12 | 2019-10-14 | Michael Uhlin | Bispecifikke antistoffer til anvendelse ved stamcelletransplantation |
WO2015130416A1 (en) | 2014-02-25 | 2015-09-03 | Immunomedics, Inc. | Humanized rfb4 anti-cd22 antibody |
TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
EP3172237A2 (en) | 2014-07-21 | 2017-05-31 | Novartis AG | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
WO2016014974A2 (en) | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
SI3221357T1 (sl) | 2014-11-20 | 2020-09-30 | F. Hoffmann-La Roche Ag | Pogoste lahke verige in načini uporabe |
EP3023437A1 (en) | 2014-11-20 | 2016-05-25 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
CN104710528B (zh) | 2015-03-13 | 2019-02-15 | 西北农林科技大学 | 一种特异性结合PRRS病毒非结构蛋白Nsp9纳米抗体及其应用 |
EP3411402B1 (en) | 2016-02-03 | 2021-12-22 | Amgen Research (Munich) GmbH | Bcma and cd3 bispecific t cell engaging antibody constructs |
BR112018076767A2 (pt) | 2016-06-21 | 2019-04-02 | Teneobio, Inc. | anticorpos de ligação a cd3 |
CA3034706A1 (en) * | 2016-08-24 | 2018-03-01 | Teneobio, Inc. | Transgenic non-human animals producing modified heavy chain-only antibodies |
WO2018052503A1 (en) | 2016-09-14 | 2018-03-22 | Teneobio, Inc. | Cd3 binding antibodies |
AU2017382251A1 (en) | 2016-12-21 | 2019-07-11 | Teneobio, Inc. | Anti-BCMA heavy chain-only antibodies |
CA3067584A1 (en) | 2017-06-20 | 2018-12-27 | Teneobio, Inc. | Anti-bcma heavy chain-only antibodies |
CN117567624A (zh) | 2017-06-20 | 2024-02-20 | 特纳奥尼股份有限公司 | 仅有重链的抗bcma抗体 |
EP3645568B1 (en) | 2017-06-30 | 2022-08-17 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Anti-b-cell maturation antigen chimeric antigen receptors with human domains |
CN111133007A (zh) | 2017-09-13 | 2020-05-08 | 特尼奥生物股份有限公司 | 与胞外酶结合的重链抗体 |
KR20200104342A (ko) | 2017-12-22 | 2020-09-03 | 테네오바이오, 인코포레이티드 | Cd22에 결합하는 중쇄 항체 |
AU2018395273A1 (en) | 2017-12-27 | 2020-08-13 | Teneobio, Inc. | CD3-delta/epsilon heterodimer specific antibodies |
CN116769032A (zh) | 2018-07-20 | 2023-09-19 | 坦尼奥第二公司 | 与cd19结合的重链抗体 |
JP2022501357A (ja) | 2018-09-21 | 2022-01-06 | テネオバイオ, インコーポレイテッド | ヘテロ二量体多重特異性抗体を精製するための方法 |
EP3870611A1 (en) | 2018-10-26 | 2021-09-01 | TeneoBio, Inc. | Heavy chain antibodies binding to cd38 |
CA3133654A1 (en) | 2019-04-05 | 2020-10-08 | Teneobio, Inc. | Heavy chain antibodies binding to psma |
AU2020291938A1 (en) | 2019-06-14 | 2022-01-20 | Teneobio, Inc. | Multispecific heavy chain antibodies binding to CD22 and CD3 |
CA3158579A1 (en) | 2019-12-18 | 2021-06-24 | Pranjali DALVI | Heavy chain antibodies binding to cd38 |
BR112022024483A2 (pt) | 2020-04-29 | 2023-02-07 | Teneoone Inc | Métodos para tratar mieloma múltiplo |
WO2021222578A1 (en) | 2020-04-29 | 2021-11-04 | Teneobio, Inc. | Multispecific heavy chain antibodies with modified heavy chain constant regions |
US20230257473A1 (en) | 2020-06-30 | 2023-08-17 | Teneobio, Inc. | Multi-specific antibodies binding to bcma |
TW202233684A (zh) | 2020-11-18 | 2022-09-01 | 美商泰尼歐生物公司 | 結合於葉酸受體α之重鏈抗體 |
CA3211138A1 (en) | 2021-02-25 | 2022-09-01 | Teneobio, Inc. | Anti-psma antibodies and car-t structures |
CN116917327A (zh) | 2021-02-26 | 2023-10-20 | 特尼奥生物股份有限公司 | 抗muc1-c抗体及car-t结构 |
TW202304994A (zh) | 2021-04-02 | 2023-02-01 | 美商泰尼歐生物公司 | 促效性抗il-2r抗體及使用方法 |
JP2024514107A (ja) | 2021-04-06 | 2024-03-28 | テネオバイオ, インコーポレイテッド | 抗cd19抗体及びcar-t構造体 |
AU2022259688A1 (en) | 2021-04-16 | 2023-10-05 | Teneobio, Inc. | Anti-cd20 antibodies and car-t structures |
WO2022271987A1 (en) | 2021-06-23 | 2022-12-29 | TeneoFour, Inc. | Anti-cd38 antibodies and epitopes of same |
WO2023004197A1 (en) | 2021-07-23 | 2023-01-26 | Teneoten, Inc. | Heavy chain antibodies binding to hepatitis b surface antigen |
-
2018
- 2018-12-21 KR KR1020207021048A patent/KR20200104342A/ko active Search and Examination
- 2018-12-21 EA EA202091557A patent/EA202091557A1/ru unknown
- 2018-12-21 PE PE2020000809A patent/PE20201171A1/es unknown
- 2018-12-21 WO PCT/US2018/067299 patent/WO2019126756A1/en active Application Filing
- 2018-12-21 CN CN201880083056.4A patent/CN111683966B/zh active Active
- 2018-12-21 CR CR20200322A patent/CR20200322A/es unknown
- 2018-12-21 BR BR112020012554-7A patent/BR112020012554A2/pt active Search and Examination
- 2018-12-21 JO JOP/2020/0157A patent/JOP20200157A1/ar unknown
- 2018-12-21 EP EP18836782.5A patent/EP3728319A1/en active Pending
- 2018-12-21 SG SG11202005880XA patent/SG11202005880XA/en unknown
- 2018-12-21 US US16/956,502 patent/US11873336B2/en active Active
- 2018-12-21 MX MX2020006494A patent/MX2020006494A/es unknown
- 2018-12-21 AU AU2018392088A patent/AU2018392088A1/en active Pending
- 2018-12-21 CA CA3086665A patent/CA3086665A1/en active Pending
- 2018-12-21 JP JP2020534858A patent/JP2021506325A/ja active Pending
-
2020
- 2020-06-18 IL IL275498A patent/IL275498A/en unknown
- 2020-06-20 CL CL2020001703A patent/CL2020001703A1/es unknown
- 2020-06-22 PH PH12020550964A patent/PH12020550964A1/en unknown
- 2020-06-22 NI NI202000050A patent/NI202000050A/es unknown
- 2020-07-21 CO CONC2020/0008925A patent/CO2020008925A2/es unknown
- 2020-07-22 EC ECSENADI202042489A patent/ECSP20042489A/es unknown
-
2022
- 2022-08-18 CL CL2022002247A patent/CL2022002247A1/es unknown
-
2023
- 2023-12-07 US US18/532,880 patent/US20240117046A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CL2020001703A1 (es) | 2020-11-06 |
MX2020006494A (es) | 2020-11-24 |
CO2020008925A2 (es) | 2020-10-30 |
US20210095022A1 (en) | 2021-04-01 |
CN111683966A (zh) | 2020-09-18 |
RU2020124188A (ru) | 2022-01-24 |
NI202000050A (es) | 2020-12-04 |
EA202091557A1 (ru) | 2020-11-18 |
CR20200322A (es) | 2021-01-12 |
CL2022002247A1 (es) | 2023-02-24 |
ECSP20042489A (es) | 2020-11-30 |
SG11202005880XA (en) | 2020-07-29 |
CA3086665A1 (en) | 2019-06-27 |
WO2019126756A9 (en) | 2019-10-17 |
CN111683966B (zh) | 2023-07-11 |
AU2018392088A1 (en) | 2020-08-13 |
US11873336B2 (en) | 2024-01-16 |
JP2021506325A (ja) | 2021-02-22 |
PH12020550964A1 (en) | 2021-03-22 |
EP3728319A1 (en) | 2020-10-28 |
IL275498A (en) | 2020-08-31 |
AU2018392088A2 (en) | 2020-08-27 |
US20240117046A1 (en) | 2024-04-11 |
BR112020012554A2 (pt) | 2020-11-24 |
WO2019126756A1 (en) | 2019-06-27 |
KR20200104342A (ko) | 2020-09-03 |
JOP20200157A1 (ar) | 2022-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20201171A1 (es) | Anticuerpos de cadena pesada que se unen a cd22 | |
CO2018013500A2 (es) | Anticuerpos anti-pd-l1 y usos de los mismos | |
CL2019003093A1 (es) | Anticuerpos anti-trem2 y métodos para utilizarlos. | |
CO2018005932A2 (es) | Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas | |
PE20181805A1 (es) | Composiciones y anticuerpos anti-tim-3 | |
ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
EA201792221A1 (ru) | Антитела против сортилина и способы их применения | |
CO2019012143A2 (es) | Formulaciones estables de anticuerpos anti-ctla4 solos y en combinación con anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso | |
PE20150002A1 (es) | Anticuerpos anti-fcrn | |
PE20171180A1 (es) | Anticuerpos anti-pd-1 y sus metodos de uso | |
PE20131209A1 (es) | Anticuerpos anti-fap | |
PE20170665A1 (es) | Anticuerpos anti-tau humanizados | |
PE20190737A1 (es) | Anticuerpos anti-cd27 | |
MX2022006461A (es) | Anticuerpos anti-axl, fragmentos de anticuerpos y sus inmunoconjugados y usos de los mismos. | |
PH12015501505A1 (en) | Antibodies that bind to tl1a and their uses | |
PE20150023A1 (es) | Proteinas de union a antigeno st2 | |
PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
AR084315A1 (es) | Anticuerpos anti-notch1 | |
CL2020002600A1 (es) | Anticuerpo anti-muerte programada-ligando 1 y su uso | |
MX2022009915A (es) | Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos. | |
AR096601A1 (es) | Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso | |
BR112021024956A2 (pt) | Anticorpos multiespecíficos de cadeia pesada que se ligam a cd22 e cd3 | |
CO2017004753A2 (es) | Anticuerpos que se unen a ccr6 | |
MX2021005048A (es) | Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos. | |
PE20230464A1 (es) | Union de anticuerpos multiespecificos a bcma |